NCT07384910

Brief Summary

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
20mo left

Started Feb 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Feb 2026Jan 2028

First Submitted

Initial submission to the registry

January 26, 2026

Completed
6 days until next milestone

Study Start

First participant enrolled

February 1, 2026

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 3, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

February 17, 2026

Status Verified

February 1, 2026

Enrollment Period

1.9 years

First QC Date

January 26, 2026

Last Update Submit

February 12, 2026

Conditions

Atheroma; Heart

Keywords

AtheromaAtherosclerosisGARPLRRC32

Outcome Measures

Primary Outcomes (1)

  • Platelet GARP expression

    The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.

    Throughout the entire study, approximately during 2 years

Secondary Outcomes (1)

  • Inflammatory profile

    Throughout the entire study, approximately during 2 years

Study Arms (3)

Acute coronary syndrome

EXPERIMENTAL

This arm includes patients undergoing coronary angiography with a final diagnostic of acute coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.

Biological: Arterial blood sample

Chronic coronary syndrome

EXPERIMENTAL

This arm includes patients undergoing coronary angiography with a final diagnostic of chronic coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.

Biological: Arterial blood sample

Control

EXPERIMENTAL

This arm includes patients undergoing coronary angiography with a final diagnostic of non significant coronary disease. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.

Biological: Arterial blood sample

Interventions

Arterial blood sampleBIOLOGICAL

An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.

Acute coronary syndromeChronic coronary syndromeControl

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Older than 18 years
  • Able to give informed consent
  • Undergoing coronary angiography.

You may not qualify if:

  • Patients younger than 18 years
  • Unable to give consent
  • Pregnancy
  • Dialysis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium

Location

MeSH Terms

Conditions

Coronary Artery DiseasePlaque, AtheroscleroticAtherosclerosis

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Christophe Beauloye, Medical Degree

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Louis Charki, Medical Degree

CONTACT

+3224362014louis.charki@uclouvain.be

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 26, 2026

First Posted

February 3, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Last Updated

February 17, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

BE(1)